Vivimusta (Bendamustine HCl) Patent Expiration, LOE Window & CMS Spending

Vivimusta (Bendamustine HCl) by Azurity: FDA Orange Book LOE 2042-07-29, 0 AB generics, $1.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN212209 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2042-07-29
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.7M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$1.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel